Olaparib elicits an up-regulation of TRAIL receptor 2 (DR5) accompanied by an increase in CCAAT enhancer binding protein (C/EBP) homology protein (CHOP)/GADD153 expression in GBM cells. The gene discussed is TNFRSF10B; the disease is glioblastoma.